{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:49:47Z","timestamp":1781311787704,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":198,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center","doi-asserted-by":"publisher","award":["P30 CA023074, NIH\/NCI R01 CA277493"],"award-info":[{"award-number":["P30 CA023074, NIH\/NCI R01 CA277493"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytokine-induced memory-like natural killer cells (CIMLNK) represent a novel form of adoptive cellular therapy that is easy to manufacture and readily available. These cells are generated after overnight stimulation of purified natural killer (NK) cells with interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18). While CIMLNK has demonstrated efficacy in patients with relapsed or refractory acute myeloid leukemia (AML), its potential application in B-cell acute lymphoblastic leukemia (B-ALL) remains unclear. Tafasitamab (TAFA), a monoclonal antibody (mAb) directed against CD19, a surface antigen expressed on B-ALL cells, has been developed to augment anti-tumor efficacy through antibody-dependent cellular cytotoxicity (ADCC), a mechanism predominantly mediated by NK cells. Consequently, we sought to assess the susceptibility of B-ALL to the combination of CIMLNK and TAFA using three B-ALL cell lines: NALM6, SUP-B15, and RS4;11. The addition of TAFA significantly augmented the cytotoxic activity, degranulation capacity, and IFN-\u03b3 production of CIMLNK. TAFA-induced ADCC was found to be dose-dependent and was abolished after CD16 blockade. Furthermore, TAFA-mediated effects against NALM6 and SUP-B15 were more pronounced in CIMLNK compared to unstimulated NK cells. In vivo, the combination of CIMLNK and TAFA led to a more pronounced survival benefit in leukemia-bearing mice. In summary, our findings suggest that this combination holds promise as a potential alternative treatment option for patients with relapsed refractory B-ALL.<\/jats:p>","DOI":"10.1093\/immadv\/ltaf025","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T07:51:09Z","timestamp":1751097069000},"source":"Crossref","is-referenced-by-count":2,"title":["Cytokine-induced memory-like NK cells combined with Tafasitamab demonstrate efficacy against B-cell acute lymphoblastic leukemia"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-6889","authenticated-orcid":false,"given":"Dimitrios","family":"Filioglou","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geovana S F","family":"Leite","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Batatinha","sequence":"additional","affiliation":[{"name":"School of Nutritional Sciences and Wellness, University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Santa-Cruz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan W","family":"Davini","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest L","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"School of Nutritional Sciences and Wellness, University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"University of Arizona Cancer Center, The University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"School of Nutritional Sciences and Wellness, University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"University of Arizona Cancer Center, The University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"Department of Immunobiology, The University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"University of Arizona Cancer Center, The University of Arizona , Tucson, AZ ,","place":["United States"]},{"name":"Department of Immunobiology, The University of Arizona , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"1","key":"2025071605582507800_CIT0001","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"24","key":"2025071605582507800_CIT0002","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025071605582507800_CIT0003","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2020.11.003","article-title":"Memory-like natural killer cells for cancer immunotherapy","volume":"57","author":"Gang","year":"2020","journal-title":"Semin Hematol"},{"issue":"12","key":"2025071605582507800_CIT0004","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"issue":"633","key":"2025071605582507800_CIT0005","doi-asserted-by":"publisher","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"7","key":"2025071605582507800_CIT0006","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/cancers13071577","article-title":"Cytokine-Induced Memory-Like NK Cells with high reactivity against acute leukemia blasts and solid tumor cells suitable for adoptive immunotherapy approaches","volume":"13","author":"Tanzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025071605582507800_CIT0007","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-Cell therapy: Cytokine Release Syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"2025071605582507800_CIT0008","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/eji.201445200","article-title":"IL-12\/15\/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation","volume":"45","author":"H\u00fcber","year":"2015","journal-title":"Eur J Immunol"},{"issue":"11","key":"2025071605582507800_CIT0009","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025071605582507800_CIT0010","doi-asserted-by":"publisher","first-page":"e154334","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"issue":"357","key":"2025071605582507800_CIT0011","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2025071605582507800_CIT0012","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025071605582507800_CIT0013","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"24","key":"2025071605582507800_CIT0014","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1182\/blood-2008-12-197061","article-title":"Therapeutic targeting of MLL","volume":"113","author":"Liedtke","year":"2009","journal-title":"Blood"},{"issue":"5-6","key":"2025071605582507800_CIT0015","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leukemia Lymphoma"},{"issue":"7","key":"2025071605582507800_CIT0016","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/leu.2012.40","article-title":"XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells","volume":"26","author":"Rafiq","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"2025071605582507800_CIT0017","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"2025071605582507800_CIT0018","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"issue":"22","key":"2025071605582507800_CIT0019","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1002\/cncr.33796","article-title":"A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed\/refractory B-precursor cell acute lymphoblastic leukemia","volume":"127","author":"Klisovic","year":"2021","journal-title":"Cancer"},{"key":"2025071605582507800_CIT0020","doi-asserted-by":"publisher","first-page":"957874","DOI":"10.3389\/fimmu.2022.957874","article-title":"Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody","volume":"13","author":"Gehlert","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"2025071605582507800_CIT0021","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","article-title":"Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis","volume":"6","author":"Vogiatzi","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025071605582507800_CIT0022","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/leu.2012.373","article-title":"The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients","volume":"27","author":"Kellner","year":"2013","journal-title":"Leukemia"},{"key":"2025071605582507800_CIT0023","doi-asserted-by":"publisher","first-page":"913215","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Co\u00ebnon","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2025071605582507800_CIT0024","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbmt.2016.11.018","article-title":"Cytokine-induced memory-like differentiation enhances unlicensed natural killer cell antileukemia and Fc\u03b3RIIIa-triggered responses","volume":"23","author":"Wagner","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2025071605582507800_CIT0025","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-12-0668","article-title":"Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands","volume":"18","author":"Chan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025071605582507800_CIT0026","doi-asserted-by":"publisher","first-page":"e22476","DOI":"10.1096\/fj.202200045R","article-title":"Enhanced development of functional human NK cells in NOD-scid-IL2rg(null) mice expressing human IL15","volume":"36","author":"Aryee","year":"2022","journal-title":"FASEB J"},{"issue":"Supplement_1","key":"2025071605582507800_CIT0027","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2019-126004","article-title":"Cytokine-induced memory-like (ML) NK cells persist for &gt; 2 months following adoptive transfer into leukemia patients with a MHC-compatible hematopoietic cell transplant (HCT)","volume":"134","author":"Foltz","year":"2019","journal-title":"Blood"},{"key":"2025071605582507800_CIT0028","doi-asserted-by":"publisher","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","article-title":"Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"issue":"20","key":"2025071605582507800_CIT0029","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"2025071605582507800_CIT0030","doi-asserted-by":"publisher","first-page":"105153","DOI":"10.1016\/j.healthpol.2024.105153","article-title":"Availability and financing of CAR-T cell therapies: a cross-country comparative analysis","volume":"149","author":"Litvinova","year":"2024","journal-title":"Health Policy"},{"issue":"3","key":"2025071605582507800_CIT0031","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.exphem.2004.11.006","article-title":"Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia","volume":"33","author":"Romanski","year":"2005","journal-title":"Exp Hematol"},{"issue":"16","key":"2025071605582507800_CIT0032","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1182\/blood.2020009871","article-title":"Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia","volume":"138","author":"Duault","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025071605582507800_CIT0033","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.beha.2016.10.010","article-title":"How important is NK alloreactivity and KIR in allogeneic transplantation","volume":"29","author":"Shaffer","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2025071605582507800_CIT0034","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"2025071605582507800_CIT0035","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/eji.201747128","article-title":"KIR downregulation by IL-12\/15\/18 unleashes human NK cells from KIR\/HLA-I inhibition and enhances killing of tumor cells","volume":"48","author":"Ewen","year":"2018","journal-title":"Eur J Immunol"},{"issue":"1","key":"2025071605582507800_CIT0036","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1186\/s12885-022-10378-w","article-title":"Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study","volume":"22","author":"Qiu","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"2025071605582507800_CIT0037","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3390\/ijms23052755","article-title":"Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in children","volume":"23","author":"Lejman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025071605582507800_CIT0038","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"96","key":"2025071605582507800_CIT0039","doi-asserted-by":"publisher","first-page":"eadk4893","DOI":"10.1126\/sciimmunol.adk4893","article-title":"Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation","volume":"9","author":"Foltz","year":"2024","journal-title":"Sci Immunol"},{"issue":"3","key":"2025071605582507800_CIT0040","doi-asserted-by":"publisher","first-page":"e1290037","DOI":"10.1080\/2162402X.2017.1290037","article-title":"Obinutuzumab-mediated high-affinity ligation of Fc\u03b3RIIIA\/CD16 primes NK cells for IFN\u03b3 production","volume":"6","author":"Capuano","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025071605582507800_CIT0041","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fimmu.2020.00202","article-title":"Glycolysis and oxidative phosphorylation play critical roles in natural killer cell receptor-mediated natural killer cell functions","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"2025071605582507800_CIT0042","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells 12","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"2025071605582507800_CIT0043","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/jleuko\/qiac020","article-title":"NOD-SCID IL2r\u03b3null mice lacking TLR4 support human immune system development and the study of human-specific innate immunity","volume":"113","author":"Aryee","year":"2023","journal-title":"J Leukoc Biol"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/5\/1\/ltaf025\/63774123\/ltaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/5\/1\/ltaf025\/63774123\/ltaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:58:34Z","timestamp":1752659914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltaf025\/8203216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltaf025","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,30]]},"article-number":"ltaf025"}}